DPYD Genotype

Fluorouracil and its pill form capecitabine are dosed on the assumption that your body can take them apart at a normal speed. Roughly one in fourteen people of European ancestry carry one of the four standard risk variants. For them, a usual dose can behave like a much larger one.

This test reads that inherited instruction. The answer never changes, and it is worth the most in the days before a first infusion or first prescription, while the dose can still be lowered.

The Enzyme That Clears the Drug

DPYD is the gene for dihydropyrimidine dehydrogenase, an enzyme that dismantles fluorouracil once it reaches your blood. More than eighty percent of a dose gets broken down this way. The small remainder is what actually works on the tumor.

Inherit a variant that weakens the enzyme and the drug lingers instead. Fast-dividing tissues take the damage first. Neutrophils, the white cells that fight infection, can collapse. The mouth and gut lining break down, and the diarrhea does not stop. Deaths from these side effects are usually estimated at about half a percent to one percent of treated patients, with risk concentrated in people who cannot clear the drug.

Four variants are the core of many routine panels: DPYD2A, DPYD13, c.2846A>T, and HapB3. Two are treated as no-function variants. Two usually leave some enzyme activity, but less than normal. Inheriting two damaging copies is far rarer, can leave almost no enzyme activity, and usually means these drugs should be avoided.

How Much the Risk Actually Changes

The numbers here are unusually stark for a genetic test. Carrying DPYD*2A and taking a full dose is not a modest risk bump. It is closer to a coin flip you lose most of the time.

Sources: Deenen et al. (row 1), Henricks et al. (row 2), Meulendijks et al. (row 3).

What this means for you: the protection comes from knowing before the first dose, not after. The 25% reduction used for HapB3 and c.2846A>T in the second study turned out not to be enough; CPIC and Dutch guidance now generally start those results at about a 50% reduction. If you carry a variant, expect the starting dose to be low and then raised over the next cycles based on how your blood counts hold up.

Does a Smaller Dose Mean Weaker Treatment?

This is the first thing most people worry about, and it is the right thing to worry about. Nobody wants to trade a side effect for a recurrence.

The logic of the reduced dose is that carriers are not getting less drug exposure. They are getting similar exposure from a smaller amount, because their bodies hold onto it longer. Measured drug levels in people on genotype-guided doses land close to those of everyone else. Matched survival comparisons have not shown worse outcomes for carriers started on reduced doses, though the evidence is still observational.

That is reassuring rather than definitive. But no one is going to run a trial that randomizes known carriers to a full dose.

A Normal Result Still Leaves Risk

Many targeted panels look for four specific variants. Those four explain only part of severe fluoropyrimidine toxicity, so a normal result lowers your odds without erasing them. People with a completely ordinary panel result still land in the hospital, and blood count monitoring during treatment matters just as much for them.

Ancestry changes what a normal result is worth. The four classic variants are most informative in European populations. A different damaging variant, c.557A>G, is seen in people of African ancestry and is not on every panel. If your ancestry is not European, check which variants the lab actually reads before relying on a normal result.

• Panel coverage: the assay only reports what it was built to look for, and a rare variant outside that list comes back silent.
• Uncertain findings: sequencing sometimes turns up a change nobody has characterized yet, which is not the same as a known risk variant and should not by itself drive a dose cut.
• Tumor-only reports: a DPYD change found only in tumor sequencing is not the same as a germline drug-dosing result unless it is confirmed in normal DNA.
• Consumer chip results: a direct-to-consumer report covering one of these positions is not clinical-grade, and an oncology team will usually want it confirmed by a clinical lab before changing a dose.

One Test, Then Use It for Life

Your genotype will read the same next year and in thirty years. There is no trend to follow and no reason to repeat the test, unless the first result came from a method that needs confirming.

What does need following is everything downstream. During a course of fluorouracil or capecitabine, blood counts get checked before each cycle, and more often in the first weeks if you carry a variant. The genotype sets the starting point and the counts steer from there.

Put the result somewhere it will survive a change of doctor. The same enzyme also handles topical fluorouracil used for some skin lesions, and severe reactions to those creams have been reported in people who cannot clear the drug. A result filed once and forgotten protects nobody.

What to Do With a Positive Result

Get it in front of whoever is writing the chemotherapy order, before the order is written. CPIC and Dutch prescribing guidance translate the genotype into a starting dose directly: one damaged copy of the gene usually means starting at roughly half, then raising the dose cycle by cycle if your counts tolerate it. Two damaged copies means these drugs are usually off the table and a different regimen is chosen instead.

If the first result came from a consumer chip or tumor-only report, confirm it with a clinical germline test before the dose is finalized. Where it is available, some teams also add a plasma uracil test. Uracil is a compound the same enzyme breaks down, so this reads the enzyme's working speed rather than the instructions for it. Europe's medicines regulator accepts either genotype testing or uracil-based testing before systemic treatment with these drugs.

Then tell your family. If you carry one variant, each parent, sibling and child has about a one in two chance of carrying the same variant. Most will never find out until a bad first cycle tells them. A genetic counselor is worth involving if you carry two damaging variants, since that pattern can be passed on in a form that affects a child's development.